ADVERTISEMENT

Psychedelics News

EnvericBiosciences

Breaking News

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

Breaking News

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

Breaking News

16 Sep 2025

With big pharma circling psychedelics, the next breakthrough may not come from tripping at all

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been...

By Madison Roberts

Breaking News, Industry, Press Releases, Psychedelic Groundbreakers, Science

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

ADVERTISEMENT

Follow us on social

Latest News

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads